1. MOH Drug Formulary (aka FUKKM)
1.1. What is it?
1.1.1. Official formulary for all preparations approved to be used in all MOH facilities
1.1.2. Contains generic name, therapeutic group, Malaysia Drug Code (MDC), prescribing categories, indications, dosage, ADRs, contraindications, interactions, precautions
1.2. Purpose
1.2.1. Tool for procurement
1.2.2. Drug use guide
1.2.3. Optimize drug usage
1.3. Management
1.3.1. Why is it important to manage?
1.3.1.1. Best decision - clinical, humanistic & economic
1.3.1.2. Objectively discriminate between superior & marginal medications
1.3.1.3. Efficient use of resources - reduce cost, affordable, improve QoL
1.3.2. Committees
1.3.2.1. FUKKM Review Panel
1.3.2.1.1. Members
1.3.2.1.2. Role
1.3.2.2. Drug Working Committee (DTC) & Technical Working Committee (TWC)
1.3.2.3. State Drug Committee
1.3.2.4. Hospital Drug Committee
1.3.3. Role of pharmacists
1.3.3.1. Lead formulary management initiatives
1.3.3.2. Coordinate DTC tasks
1.3.3.3. Make recommendations based on sound clinical evidence
1.3.3.4. Guide DTC thru drug selection process
1.3.3.5. Develop policies, guidelines and utilization strategies
1.4. Amendments
1.4.1. According to the types and eligibility of dossier submission
1.4.2. Subject to the workflow in the Dossier Submission Guidelines
2. Essential Drug List
2.1. What is essential drugs?
2.1.1. medicines that satisfy priority healthcare needs of the populations
2.1.2. should always available in adequate amount, appropriate dosage forms, assured quality and affordable price
2.1.3. consist of 30 therapeutic groups
2.2. Functions of National Essential Medicine List (NEML)
2.2.1. Public sector drug procurement, distribution & utilisation
2.2.2. Training new healthcare professionals & public education
2.2.3. Drug info to healthcare providers
2.2.4. Support domestic pharma industries
2.2.5. Drug financing & reimbursement schemes
2.2.6. Drug donations
2.3. NEML Committee
2.3.1. Medicine experts
2.3.2. Pharmacy
2.3.3. Dentistry
2.3.4. Pharmacology
2.3.5. Public health
2.3.6. Consumer affairs
2.3.7. Health economics
2.4. Selection process
2.4.1. regularly updated
2.4.2. ensure drug quality
2.4.3. continued development
2.4.4. independent & transparent
2.4.5. wide consultation with all related parties (healthcare professionals, pharma mfg, consumer org)